SOLENO THERAPEUTICS INC Selling, General and Administrative Expense
SOLENO THERAPEUTICS INC reported Selling, General and Administrative Expense of $50.37 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-05-07
- SOLENO THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2026-03-31 was $50.37M, a 72.15% increase year-over-year.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2025-12-31 was $40.88M, a 9.58% increase year-over-year.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2025-09-30 was $33.75M, a 31.39% decline year-over-year.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2025-06-30 was $28.24M, a 159.33% increase year-over-year.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for fiscal 2025 was $132.13M, a 24.81% increase from fiscal 2024.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for fiscal 2024 was $105.86M, a 685.26% increase from fiscal 2023.
- SOLENO THERAPEUTICS INC selling, general and administrative expense for fiscal 2023 was $13.48M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $50.37M 10-Q · filed 2026-05-07 | $91.25M derived: sum of 2 quarters · filed 2026-05-07 | $125.00M derived: sum of 3 quarters · filed 2026-05-07 | $153.24M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $40.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $74.63M derived: sum of 2 quarters · filed 2026-02-25 | $102.87M derived: sum of 3 quarters · filed 2026-02-25 | $132.13M 10-K · filed 2026-02-25 |
| 2025-09-30 | $33.75M 10-Q · filed 2025-11-04 | $61.99M derived: sum of 2 quarters · filed 2025-11-04 | $91.25M 10-Q · filed 2025-11-04 | $128.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $28.24M 10-Q · filed 2025-08-06 | $57.50M 10-Q · filed 2025-08-06 | $94.80M derived: sum of 3 quarters · filed 2026-05-07 | $144.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $29.26M 10-Q · filed 2026-05-07 | $66.56M derived: sum of 2 quarters · filed 2026-05-07 | $115.76M derived: sum of 3 quarters · filed 2026-05-07 | $126.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $37.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.50M derived: sum of 2 quarters · filed 2026-02-25 | $97.39M derived: sum of 3 quarters · filed 2026-02-25 | $105.86M 10-K · filed 2026-02-25 |
| 2024-09-30 | $49.20M 10-Q · filed 2025-11-04 | $60.09M derived: sum of 2 quarters · filed 2025-11-04 | $68.56M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $10.89M 10-Q · filed 2025-08-06 | $19.36M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $8.47M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $13.48M 10-K · filed 2026-02-25 |